This article compares the two the way the published evidence actually supports, which is more sobering than the marketing
For current product specifications, complete service details, and eligibility requirements, visit the official Direct Meds website
Start your intake Understanding Tirzepatide Discontinuation and Weight Rebound Weight return after stopping GLP-1 or tirzepatide therapy occurs because the underlying metabolic driversappetite regulation, insulin sensitivity, and hunger hormone signalingreturn to baseline without continued medication support
In November 2025, however, President Trump announced that Zepbound and other GLP-1s would be covered by Medicare starting as early as April 2026
While GLP-1 physiology informs the development of therapeutic agents, the native peptide itself cannot be practically administered for disease management